All In Biotech

Drug Trial Radar · NCT00123253

TH9507 in Patients With HIV-Associated Lipodystrophy

A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg Dose of TH9507, a Growth Hormone Releasing Factor Analog, in HIV Patients With Excess of Abdominal Fat Accumulation

Last checked: Nov 20, 2026Latest source record: Nov 27, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 412 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

412

Actual

Start

Jun 2005

Primary completion

Nov 2006

Study completion Apr 2007

Sponsor

Lead sponsor
TheratechnologiesIndustry
Sponsor type
Industry
First posted
Jul 22, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

HIV lipodystrophy affects a significant proportion of patients treated with combination antiretroviral therapy (ART) and is characterized by excess visceral fat accumulation and loss of extremity and subcutaneous fat, in association with dyslipidemia and insulin resistance. Data from a previous randomized, placebo-controlled trial demonstrated that daily administration of 2mg TH9507, a growth hormone releasing factor (GRF), to HIV patients with an excess of abdominal fat accumulation for 12 weeks resulted in decreases in visceral adipose tissue (VAT) and trunk fat, with no significant changes in limb fat and subcutaneous adipose tissue (SAT). This study is aimed at further assessing the efficacy and safety of 2 mg TH9507 in a larger population of HIV patients treated with ART and experiencing an excess of abdominal fat accumulation.

Conditions

  • HIV Infections
  • Lipodystrophy

Interventions

  • TH9507Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Visceral adipose tissue (VAT)

Locations

42 sites in 2 countries. Site status is shown where the registry gives one.

  • UCLA School of Medicine

    Los Angeles, California

  • Office of Dr. Michael Somero

    Palm Springs, California

  • UCSD Medical Center

    San Diego, California

  • Kaiser Permanente

    San Francisco, California

  • AIDS Research Alliance

    West Hollywood, California

  • Capital Medical Associates

    Washington D.C., District of Columbia

  • Bach & Godofsky

    Bradenton, Florida

  • Office of Dr. Gary Richmond

    Fort Lauderdale, Florida

  • Care Resource Miami

    Miami, Florida

  • Orlando Immunology Center

    Orlando, Florida

  • Infectious Disease Associates

    Sarasota, Florida

  • Treasure Coast Infectious Disease Consultant (TDIDC)

    Vero Beach, Florida

  • AIDS Research Consortium Atlanta (ARCA)

    Atlanta, Georgia

  • Northern Healthcare

    Chicago, Illinois

  • Rush University Medical Center

    Chicago, Illinois

  • Indiana University Department of Medicine

    Indianapolis, Indiana

  • Institute of Human Virology

    Baltimore, Maryland

  • Johns Hopkins University School of Medicine

    Baltimore, Maryland

  • Community Research Initiative of New England

    Boston, Massachusetts

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Tufts University School of Medicine

    Boston, Massachusetts

  • Community Research Initiative of New England (CRI West)

    Springfield, Massachusetts

  • Hennepin County Medical Centre

    Minneapolis, Minnesota

  • AIDS Community Research Initiative of America

    New York, New York

  • Bellevue Hospital Center New York University

    New York, New York

  • St Luke's Roosevelt Hospital Centre

    New York, New York

  • St Vincent Catholic Medical Centre

    New York, New York

  • University of Cincinnati Medical Center

    Cincinnati, Ohio

  • Fanno Creek Clinic, LLC

    Portland, Oregon

  • Drexel University College of Medicine

    Philadelphia, Pennsylvania

  • Central Texas Clinical Research

    Austin, Texas

  • Dallas VA Medical Centre

    Dallas, Texas

  • The University of Texas Medical School

    Houston, Texas

  • Infectious Disease Physicians Inc.

    Annandale, Virginia

  • Swedish Medical Center

    Seattle, Washington

  • Southern Alberta Clinic

    Calgary, Alberta, Canada

  • St-Paul's Hospital

    Vancouver, British Columbia, Canada

  • Sunnybrook and Women College Health Sciences Centre

    Toronto, Ontario, Canada

  • Windsor Regional Hospital

    Windsor, Ontario, Canada

  • Clinique Médicale du Quartier Latin

    Montreal, Quebec, Canada

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.